Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Asoori, Sireesha [1 ]
Martin, Thomas [1 ]
Wolf, Jeffrey [1 ]
Chung, Alfred [1 ]
Arora, Shagun [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CT; teclistamab; relapsed refractory multiple myeloma; infections;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT-630
引用
收藏
页码：S536 / S537
页数：2
相关论文
共 50 条
  • [31] Real-World Analysis of Teclistamab Treatment for Relapsed Refractory Multiple Myeloma in Two Belgian University Hospitals
    Jadot, Gaspard
    Depaus, Julien
    Vekemans, Marie-Christiane
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S59 - S59
  • [32] ADJUSTED COMPARISON OF TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN'S CHOICE (RWPC) OF THERAPY IN PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mateos, M., V
    Chari, A.
    Usmani, S. Z.
    Goldschmidt, H.
    Weisel, K.
    Qi, K.
    Londhe, A.
    Nair, S.
    Lin, X.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Parekh, T.
    Marshall, A.
    Slavcev, M.
    Moreau, P.
    VALUE IN HEALTH, 2023, 26 (12) : S5 - S5
  • [33] Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
    Davis, James A.
    Snyder, Jordan
    Rice, Mikhaila
    Moore, Donald C.
    Cahoon, Christopher
    Julian, Kelley
    Wagner, Charlotte B.
    Granger, Katelynn
    Green, Kimberly M.
    Atrash, Shebli
    Hill, Hailey
    Mcelwee, Jessica
    Elsey, Grace
    Khouri, Jack
    Rudoni, Joslyn
    Mahmoudjafari, Zahra
    Nachar, Victoria R.
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [34] COMPARATIVE EFFECTIVENESS OF TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN'S CHOICE OF THERAPY (RWPC) FOR PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Krishnan, A.
    Nooka, A.
    Chari, A.
    Garfall, A. L.
    Martin, T.
    Nair, S.
    Lin, X.
    Qi, K.
    Londhe, A.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Parekh, T.
    Marshall, A.
    Slavcev, M.
    Usmani, S. Z.
    VALUE IN HEALTH, 2023, 26 (12) : S37 - S37
  • [35] Real World Outcomes with Elotuzumab-Based Therapies for Patients with Relapsed Refractory Multiple Myeloma (RRMM): A Mayo Clinic Experience
    Parrondo, Ricardo
    Das, Saurav
    Hodge, David
    Sledge, Hanna
    Bergsagel, P. Leif
    Fonseca, Rafael
    Leung, Nelson
    Kapoor, Prashant
    Gertz, Morie
    Buadi, Francis
    Dispenzieri, Angela
    Elliott, Jamie
    Fernandez, Andre
    Chanan-Khan, Asher
    Roy, Vivek
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S272 - S273
  • [36] Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/Refractory Multiple Myeloma (rrMM) Patients
    Shao, Changxia
    Monberg, Matthew
    Cao, Xiting
    Zhou, Wei
    Zhong, Yichen
    Marinello, Patricia
    BLOOD, 2016, 128 (22)
  • [37] Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Powers Happ, Lindsey
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
    Davis, James A.
    Snyder, Jordan
    Rice, Mikhaila
    Moore, Donald C.
    Cahoon, Christopher
    Julian, Kelley
    Wagner, Charlotte B.
    Granger, Katelynn
    Green, Kimberly M.
    Atrash, Shebli
    Hill, Hailey
    Mcelwee, Jessica
    Elsey, Grace
    Khouri, Jack
    Rudoni, Joslyn
    Mahmoudjafari, Zahra
    Nachar, Victoria
    BLOOD, 2024, 144 : 2382 - 2383
  • [39] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    D'Estrube, Tim
    Fry, Mark
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167
  • [40] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
12345